1-丙基-L-脯氨酰胺 | 114812-35-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-丙基-L-脯氨酰胺
• 英文名称: (-)-(S)-1-propyl-2-pyrrolidinecarboxamide
• 英文别名: (S)-N-propylprolinamide；(S)-1-Propylpyrrolidine-2-carboxamide；(2S)-1-propylpyrrolidine-2-carboxamide
• CAS: 114812-35-0
• 化学式: C₈H₁₆N₂O
• 分子量: 156.228
• InChiKey: GFSPQSVWDMEDQH-ZETCQYMHSA-N

物化性质

• 沸点：
  297.0±29.0 °C(Predicted)
• 密度：
  1.025±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-丙基-L-脯氨酰胺 在 红铝 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 4.0h， 以63%的产率得到(-)-(S)-2-aminomethyl-1-propylpyrrolidine
  参考文献：
  名称：

  Hoegberg, Thomas; Raemsby, Sten; Stroem, Peter, Acta Chemica Scandinavica, 1989, vol. 43, # 7, p. 660 - 664

  摘要：

  DOI：
• 作为产物：
  描述：

  (-)-methyl (S)-1-propyl-2-pyrrolidinecarboxylate 在 氰化钠 、 氨 作用下， 以 甲醇 为溶剂， 反应 72.0h， 以79%的产率得到1-丙基-L-脯氨酰胺
  参考文献：
  名称：

  Hoegberg, Thomas; Raemsby, Sten; Stroem, Peter, Acta Chemica Scandinavica, 1989, vol. 43, # 7, p. 660 - 664

  摘要：

  DOI：

文献信息

• INHIBITORS OF HIV REPLICATION
  申请人：STURINO Claudio

  公开号：US20100261714A1

  公开（公告）日：2010-10-14

  Compounds of formula (I): wherein R 1 , R 2 , A 1 , A 2 , A 3 , A 4 , X and Y are as defined herein, are useful as inhibitors of HIV replication.

  式(I)的化合物： 其中R1、R2、A1、A2、A3、A4、X和Y如本文所定义，可用作HIV复制抑制剂。
• Novel Receptor Antagonists and Their Methods of Use
  申请人：Chambers J. Laura

  公开号：US20080009541A1

  公开（公告）日：2008-01-10

  The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.

  本发明涉及一种新型的氧代脯氨酰胺衍生物，其化学式为（I），可以调节P2X7受体功能，并能够拮抗P2X7受体上ATP的作用，以及利用这些化合物或其药物组合物治疗由P2X7受体介导的疾病，例如疼痛、炎症和神经退行性疾病。
• Efficient stereoconservative synthesis of 1-substituted (S)- and
  申请人：Astra Lakemedel Aktiebolag

  公开号：US05300660A1

  公开（公告）日：1994-04-05

  Stereoconservative method for preparation of an (R)- or (S)-isomer of the compound of the formula I with at least 95% optical purity ##STR1## wherein R.sup.1 is a hydrogen atom, a saturated or unsaturated lower alkyl group, a cycloalkyl group, or a group (CH.sub.2).sub.m Ph wherein m is 0-3 and Ph is a substituted or unsubstituted phenyl group including 1) O,N-dialkylation, directly or stepwise of (R)- or (S)-proline 2) aminolysis 3) reduction to formation of the (R)- or (S)-isomer of the compound of the formula I, and new intermediates II and III in optical active form obtained by the reaction steps above and wherein R.sup.2 is defined as R.sup.1 above. ##STR2##

  用立体保守方法制备化合物的(R)-或(S)-异构体，其光学纯度至少为95%，其中R.sup.1是氢原子、饱和或不饱和的较低烷基基团、环烷基基团，或基团(CH.sub.2).sub.m Ph，其中m为0-3，Ph是取代或未取代的苯基团，包括1）(R)-或(S)-脯氨酸的直接或分步O，N-二烷基化，2）氨解作用，3）还原生成化合物的(R)-或(S)-异构体的方法，以及通过上述反应步骤获得的具有光学活性形式的新中间体II和III，其中R.sup.2被定义为上述的R.sup.1。
• BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE
  申请人：AMGEN INC.

  公开号：US20160046625A1

  公开（公告）日：2016-02-18

  Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.

  公式（I）的化合物是阻断无形淋巴瘤激酶的有用抑制剂。 公式（I）的化合物具有以下结构：其中变量的定义在此提供。
• N-Fluoroalkylated and N-alkylated analogs of the dopaminergic D-2 receptor antagonist raclopride
  作者：G. S. Lannoye、Stephen M. Moerlein、D. Parkinson、M. J. Welch

  DOI：10.1021/jm00171a017

  日期：1990.9

  A series of raclopride [(S)-2-[(3,5-dichloro-6-methoxy-2- hydroxybenzamido)methyl]-1-ethylpyrrolidine] derivatives bearing pyrrolidino N-fluoroalkyl or -alkyl substituents were synthesized and evaluated as potential dopaminergic receptor-based positron tomography radiopharmaceuticals. Radiosynthetic procedures for producing the corresponding N-[18F]fluoroalkylated analogues of raclopride from 18F- (beta+, t1/2 = 110 min) in high specific activity were also developed. In vitro binding assays using competitive displacement of [3H]spiperone from primate caudate tissue indicated that the N-alkylated analogues of raclopride had Ki values of 5-40 nM, whereas the corresponding values for analogous N-fluoroalkylated derivatives ranged from 90-160 nM. The relatively low D-2 binding affinity of these fluorinated salicylamides was corroborated by in vivo tissue biodistribution results in rodents. On the basis of structure-binding correlations, the impact of intramolecular hydrogen bonding, ligand basicity, and steric bulk on the affinity of the benzamides for D-2 receptor binding are discussed. Strategies are presented for the development of alternative fluorinated salicylamides that are both receptor active and metabolically stable.